Related Experiment Video

Updated: Jun 5, 2025

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

876

Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors

Émilie Lavallée1, Maëline Roulet-Matton1, Viviane Giang1

  • 1Faculté de Pharmacie, Université de Montréal, Montréal, Canada.

Life Science Alliance
|December 10, 2024
PubMed

Insights

Targeting Polo-like kinase 1 (PLK1) shows promise in cancer, but resistance is an issue. Mitochondrial factors and specific RSK inhibition can improve PLK1 inhibitor effectiveness and reduce inflammation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Polo-like kinase 1 (PLK1) inhibitors are promising anticancer agents but face challenges in clinical translation due to low efficacy and tumor relapse.
  • Understanding resistance mechanisms is crucial for improving targeted cancer therapies.

Purpose of the Study:

  • To identify mitochondrial protein signatures that dictate sensitivity to PLK1 inhibition in human melanoma.
  • To explore strategies for overcoming resistance to PLK1-targeted therapies.

Main Methods:

  • Analysis of mitochondrial protein signatures in melanoma cell lines upon PLK1 inhibition or gene silencing.
  • Investigating the role of mitochondrial DNA and ABCD1 transporter in PLK1 inhibitor sensitivity.
  • Evaluating the effects of p90 ribosomal S6 kinase (RSK) inhibitors on PLK1 activity and cellular phenotype.

Main Results:

  • PLK1 inhibition induces apoptosis in sensitive cells and a pro-inflammatory, dedifferentiated phenotype in resistant cells.
  • Mitochondrial DNA depletion and ABCD1 transporter silencing enhance sensitivity to PLK1 inhibition and reduce inflammation.
  • Nonselective RSK inhibitors act via PLK1, causing proliferation inhibition and inflammation; specific RSK inhibition is anti-inflammatory and promotes antigen presentation.

Conclusions:

  • Mitochondrial pathways significantly influence cellular response to PLK1 inhibition, impacting phenotype switching.
  • Targeting mitochondrial factors and specific RSK offers a precision medicine approach to enhance PLK1 inhibitor efficacy and manage treatment-related inflammation.

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.1K
Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

8.6K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K